Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 13/20 | 1.00 |
| ▸ | INSR | P06213 | 12/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.90 |
| ▸ | EGFR | P00533 | 3/20 | 0.86 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.86 |
| ▸ | AURKA | O14965 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | BRAF | P15056 | 1/20 | 0.85 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310718 | 0.96 | INSR (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL310149 | 0.96 | INSR (0.93) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL309532 | 0.95 | IGF1R (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL310171 | 0.95 | IGF1R (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL311057 | 0.95 | IGF1R (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL310688 | 0.95 | IGF1R (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL309968 | 0.94 | IGF1R (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL310293 | 0.94 | IGF1R (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL310120 | 0.94 | IGF1R (1.00) | IGF1RINSRMAPK14EGFRERBB2 | |
| SCHEMBL309764 | 0.94 | INSR (1.00) | IGF1RINSRMAPK14EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | IGF1R 633/4885INSR 814/4885MAPK14 333/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | IGF1R 633/4885INSR 814/4885MAPK14 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.